Podcasts about Dexcom

If you've been working harder and harder to improve your blood sugars but still feel stuck, this message is for you.Many people with Type 1 Diabetes hit a point where more effort doesn't create better results—it only creates more frustration and burnout.The breakthrough often comes from strategy, precision, and understanding what's really holding you back.Remember: Sometimes the hose isn't too short... it's just wrapped around the table.Work smarter, not harder. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care. Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a remarkable 30.3% weight reduction over two years in a Phase 3 trial. This drug, a triple agonist targeting glucagon-like peptide-1 receptors, regulates appetite and energy balance effectively. Such results not only highlight its potential as a transformative therapy for obesity but also position Eli Lilly prominently within metabolic disorder treatment landscapes. With global obesity rates on the rise, retatrutide's success could meaningfully impact public health strategies and pharmaceutical approaches to managing weight. In the oncology sector, Johnson & Johnson's acquisition of Firefly Bio for $1 billion is a strategic move aimed at enhancing their oncology pipeline with Firefly's Degrader Antibody Conjugate platform. This technology is designed to target KRAS-driven tumors, which are notoriously difficult to treat, prevalent in cancers such as pancreatic and colorectal cancer. By integrating Firefly's innovative platform, J&J aims to offer new hope for patients dealing with these challenging cancers. Turning to regulatory developments, the FDA has expanded Pfizer's Hympavzi label to include pediatric patients aged six and older with hemophilia A and B. This decision follows robust Phase 3 results that demonstrate Hympavzi's efficacy as a prophylactic treatment in this young population. The expanded label underscores efforts to address pediatric needs in areas traditionally focused on adults, thus broadening treatment options for young patients with bleeding disorders. In Europe, Chiesi's Loxujta (lomitapide) has gained EU pediatric label expansion for treating homozygous familial hypercholesterolemia, supported by strong Phase 3 data. This expansion aligns with a growing trend toward personalized medicine, tailoring treatments to specific genetic profiles even in younger populations. Collaborative efforts in biotechnology are also gaining momentum. GSK has partnered with Engitix to research liver fibrosis regression through extracellular matrix-targeted drug discovery. This collaboration highlights an industry shift towards leveraging biotechnology for innovative therapeutic solutions. Hikma Pharmaceuticals has shown confidence in the U.S. pharmaceutical manufacturing sector by committing $267 million to expand its facilities in Ohio. This expansion enhances Hikma's production capabilities while creating 350 jobs, positively impacting local economies and ensuring robust supply chain capabilities for essential medicines. The clinical trial landscape is vibrant with promising data across various therapeutic areas. Amgen's Repatha (evolocumab) has demonstrated cardiovascular risk reduction in high-risk diabetes patients without prior heart attacks or strokes, reinforcing its role not just in cholesterol management but also in broader cardiovascular risk mitigation strategies. Dexcom has made strides in metabolic diseases with its G7 continuous glucose monitor showing significant benefits for non-insulin-dependent type 2 diabetes patients. This development illustrates the increasing integration of digital health technologies into chronic disease management. Moreover, emerging treatments like Sciwind Biosciences' ecnoglutide have shown superior weight loss outcomes compared to existing therapies such as semaglutide. Such head-to-head comparisons are crucial for advancing competitive therapeutic landscapes and optimizing patient outcomes. In summary, the pharmaceutical and biotech sectors are experiencing transformative changes driven by scientific advancements and strategic collaborations. These developments not only expand treatment options across various therapeutic areas but also signify a shift toward more personalized and integrated healthcare solutions that could significantly impact patient care and drug development pathways globally. As these trends continue to evolve, they will likely drive further progressions in how pharmaceutical companies approach drug development and regulatory engagements, ultimately benefiting patients worldwide through more effective and personalized treatment modalities. Stay tuned for more updates from Pharma Daily as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

In this BONUS episode of Diabetes Connections.. I'm talking to Dexcom CEO Jake Leach. Lots of news from Dexcom as they presented new information this weekend at the annual ADA Conference. Did you also know that the G6 will stop being made in less than a month, that Dexcom is developing a new product for hospitals, why they're talking about potassium and we look at the customer advisory counsel report. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Advisory Counsel Report: https://dexcom.a.bigcontent.io/v1/static/en-us-customer-advisory-council-report-2026 Dexcom Investor Report (with the hospital device and potassium info): https://investors.dexcom.com/overview/default.aspx Dexcom Connect Study: https://www.drugdeliverybusiness.com/dexcom-connect-study-g7-ada-2026/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

Roger Neel sold his SaaS company at $100M+ ARR, took three hours off, and dove straight into a health tech startup backed by Google Ventures and Dexcom. In this conversation, Roger breaks down the full arc — from founding Mavenlink in the teeth of the 2008 financial crash, to grinding through 13 years of customer base churn, fundraising rounds, and eventually selling to PE. He also shares what he'd do completely differently if he were starting today with AI tools at his disposal to build a 9-figure business. We get into his framework for evaluating whether a business is actually defensible (he calls it the 3 Ds), why most SaaS companies don't need a moat until they're past $10M, what really happens when you sell to a PE firm, and how a regulatory curveball nearly killed his new company Signos right before launch.   Key Takeaways with Roger Neel (01:48) Building A $100M Company In The AI Era (04:03) The Origin Story Of Mavenlink (07:01) The Future Of SaaS And Custom Software (09:25) The Three Ds: Demand, Differentiation, Defensibility (17:18) Why He Jumped Into Health Tech (19:26) Finding Your Actual Passion In Business (21:51) How Signos Revolutionized Continuous Glucose Monitoring (27:27) When A Regulatory Shift Breaks Your Model (33:16) Bootstrapping Vs. Raising Capital (38:09) The 13-Year Growth Arc To Exit (41:54) Going Up Market Faster With AI  (46:43) Selling To PE: How The Deal Actually Works (48:48) Why Keep Raising Instead Of Selling Earlier (50:24) PE vs. IPO (51:02) Picking The Right PE Firm (58:03) Advice For Raising Capital Today (59:30) AI Tools Entrepreneurs Should Be Using   Watch on YouTube: https://youtu.be/ktl53U-LLL0     Let's Connect: Website | Instagram | YouTube | TikTok | Twitter | Facebook

Dexcom CEO Jake Leach and CTO Peter Simpson discuss G7 sensor performance, gooseneck fixes, adhesive improvements, customer support, replacement policies, and self-calibrating G8 technology shaping diabetes care at scale forward. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

 Living with diabetes doesn't have to mean constant highs, lows, and mental exhaustion.In this conversation, a 25-year T1D shares how she went from 60–70% time in range to 78%—and even 95% on easier days—while actually living her life again.Less stress, more energy, and finally space to just be present. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

May 28, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Future Snoops x Spate report finds consumers pulling back from optimization culture, with energy healing reaching 30M+ monthly searches and tai chi interest up 22% Signos raises $20M backed by GV and Dexcom to expand AI metabolic health platform combining continuous glucose monitoring with coaching, growing tenfold in six months Oura introduces Ring 5 40% smaller than previous generation with blood pressure signals, nighttime breathing analysis, GLP-1 tracking, and AI-powered care partnership More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

 I just had my diabetes supplies changed by insurance without anyone even telling me.No notice. No consent. Just a different order showing up at my door.So I had to call in and figure it out myself.And instead of arguing, I used a few simple psychology-based tactics that completely changed how the conversation went… and I ended up not only fixing the issue, but getting extra supplies approved too.I broke down exactly what I did in this video — step by step — because this is something a lot of people living with diabetes quietly deal with, but don't really talk about. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Ken and Graham dive into one of the biggest frustrations people living with Type 1 diabetes face: the gap between medical care and real-life diabetes management.The conversation starts with a powerful discussion around endocrinologists, insulin safety, and why most healthcare providers are forced to prioritize preventing dangerous lows over helping patients aggressively optimize blood sugars. Ken explains how fear of hypoglycemia, liability, and limitations within the healthcare system shape the guidance many people receive.From there, the episode evolves into a deep real-world conversation around:insulin pumps and automationdawn phenomenoninsulin resistance from stresslearning patterns and building “checklists”trusting Dexcom trend arrowsand how to actually troubleshoot blood sugar problems in real timeGraham also shares a brutally honest look into the mental frustration of waking up high from dawn phenomenon despite doing “everything right,” leading to a conversation many people with diabetes quietly relate to but rarely talk about openly.This episode blends education, emotional reality, and practical problem-solving into one of the most relatable diabetes conversations yet.

What if your new patient visit didn't start with a 200-page ER record dump, scattered portal logins, and a patient saying "I think mom had some kind of cancer"? In this episode of My DPC Story, Dr. Maryal Concepcion sits down with Anna Smith, RN, MPH, CEO of Vivid Vault Health Solutions, to talk about a patient-owned, multi-generational health navigation platform built to strengthen the physician-patient relationship, not replace it.Anna shares her realization that healthcare collects massive amounts of data but rarely puts it in patients' hands in a way they can actually use. That moment became Vivid Vault, a bootstrapped, non-VC, non-PE-funded platform designed to help families consolidate records across generations so DPC physicians can finally practice with the comprehensive, portable patient story we've always needed. Big Trees MD is an early adopter, and Dr. Concepcion walks through exactly why.If you want to give your patients a comprehensive, portable, patient-owned record system without adding another six-figure EMR to your stack, book a leadership call at vividvaulthealth.org or email together@vividvaulthealth.org. Download the Vivid Vault app in the Apple Store starting April 22. If this episode moved you, leave a five-star review on Apple Podcasts.What You'll LearnWhy fragmented records cost DPC physicians time, accuracy, and patient retention. How Vivid Vault works as a health navigator, not a new EMR or added workflow. Why multi-generational, family-linked records matter, and how permissions, proxies, and minors are handled. How PROMIS assessments give physicians insight between visits. How wearable data (Apple Health, Oura, WHOOP, Garmin, Dexcom soon) is timestamped and clinically usable. Why patient-owned data is non-negotiable and what happens if a patient leaves your practice or the platform. How LLM-assisted review surfaces what matters in a 200-page ER packet without replacing clinical judgment. Why B2C with a DPC practice discount keeps the financial burden off clinics.About Our GuestAnna Smith, RN, MPH, is the CEO and founder of Vivid Vault Health Solutions, a Colorado-based, bootstrapped health navigation platform. Her background spans bedside nursing, public health, medical records administration in cardiology, and patient advocacy. She is a mother of three and builds alongside a leadership team whose lived experience, including parenting a heart transplant recipient, shapes every design decision.ResourcesFind the Vivid Vault app in the Apple App store today!Website: vividvaulthealth.org (scroll to bottom right and click "Schedule with Leadership") Email: together@vividvaulthealth.org Connect with My DPC StoryStart Here page for every stage of your DPC journey: mydpcstory.comSupport the showGET your FREE MONTHLY BUSINESS TOOL DOWNLOADBecome A My DPC Story PATREON MEMBER! SPONSOR THE PODMy DPC Story VOICEMAIL! DPC SWAG!FACEBOOK * INSTAGRAM * LinkedIn * TWITTER * TIKTOK * YouTube

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

After 47 years with Type 1 Diabetes, Cathy thought she had already learned everything… until she discovered predictability.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special in-studio episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reflect on major themes and anticipated developments ahead of the upcoming American Diabetes Association (ADA) Scientific Sessions 2026.The discussion opens with Bellini congratulating Isaacs on receiving the ADA Outstanding Educator in Diabetes Award, prompting a conversation centered on Isaacs' forthcoming presentation, “Behind Every Number Is a Story: Transforming Diabetes Care and Education through Technology and Human Connection.” Isaacs reflects on the rapid evolution of diabetes technology over the last decade, from limited continuous glucose monitoring (CGM) access and the emergence of early automated insulin delivery (AID) systems to the integration of artificial intelligence into diabetes care, while emphasizing that successful care remains grounded in human connection and individualized patient experiences.The hosts then preview several therapeutic areas expected to dominate discussion at ADA, particularly the expanding pipeline of incretin-based therapies. Bellini and Isaacs discuss growing excitement surrounding GLP-1, GIP, and glucagon receptor agonists, including anticipated data from triple agonist agents such as retatrutide and emerging oral therapies like orforglipron. They highlight the significance of improved weight-loss efficacy in people with type 2 diabetes (T2D), broader cardiometabolic applications, and the increasing importance of treatment accessibility and affordability. The conversation also explores the expanding role of these therapies in addressing cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and other obesity-related comorbidities.Technology advancements represent another major focus of the episode. Isaacs and Bellini discuss new CGM-driven insulin titration tools, including Dexcom's Smart Basal feature, designed to address therapeutic inertia among people with T2D using basal insulin. They also examine the growing role of CGM in broader patient populations and discuss evolving ADA recommendations supporting CGM access for any individual likely to benefit from the technology. The hosts express particular enthusiasm for the anticipated arrival of continuous ketone monitoring, including dual glucose-ketone sensors, and consider how these devices may transform diabetic ketoacidosis prevention and patient education, particularly for individuals with type 1 diabetes (T1D).The conversation also highlights continued innovation in insulin delivery systems and connected diabetes devices. Isaacs and Bellini discuss progress toward fully closed-loop AID systems, including ongoing studies evaluating meal-unannounced insulin delivery in T2D. They review emerging insulin pump technologies from Medtronic, including updates to the MiniMed platform and the integration of connected insulin pen systems with real-time CGM data through the MiniMed Go app. The hosts emphasize the importance of preserving therapeutic choice for people who prefer injections over pump therapy or who seek temporary alternatives to wearable devices.Toward the conclusion of the episode, both hosts preview their own ADA presentations. Isaacs discusses an upcoming session on inhaled insulin that will use simulated patient scenarios to explore shared decision-making and individualized therapy selection. Bellini highlights her session focused on skin complications related to diabetes technologies, including allergic reactions and adhesive-related challenges that can interfere with sustained device use. Together, they underscore the importance of addressing practical barriers to technology adoption while continuing to expand therapeutic and technological options for people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Los futuros de índices de Bolsa estadounidense caen con ganas ante el repunte de los rendimientos de los bonos por los temores inflacionistas. El del 10 años se va a su nivel más alto desde principios de junio de 2025. Los inversores asumen que los tipos de interés subirán más rápido de lo esperado y que el crecimiento económico se verá afectado. Hoy preguntamos si es una señal de alarma que inversores tecnológicos han estado ignorando, cegados por unos beneficios brillantes y unas expectativas de beneficios aún más deslumbrantes. Además, la a cumbre entre EEUU y China concluye sin avances significativos, tras unas conversaciones entre ambas naciones que han abarcado una amplia agenda que incluía los aranceles, Irán y Taiwán. Valores protagonistas en América son Applied Materials, Dexcom y aerolíneas. Lo analizamos todo con Antonio Castelo, de Ibroker. Vemos, como todos los viernes, operativas con futuros y niveles de precios en valores Ibex con Gerardo Ortega.

100% Time in Range at Disneyland No rigid rules. No perfect conditions. Just learning how to adapt, think critically, and stay one step ahead.Your diabetes shouldn't stop you from living your life. The goal isn't perfection — it's freedom with control. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a slew of advances in diabetes technology and treatments, starting with the US Food and Drug Administration (FDA)'s recent approval of the Tandem automated insulin delivery system for use during pregnancy in individuals with type 1 diabetes. The conversation centers on findings from the CIRCUIT trial, which demonstrated significant improvements in time in range among pregnant patients, a population historically challenging to manage because of stringent glycemic targets. Isaacs and Bellini review practical considerations from the study, including the use of continuous sleep mode to target tighter glucose ranges and proactive optimization of basal rates, correction factors, and carbohydrate ratios to improve outcomes. They emphasize that FDA approval now allows clinicians and manufacturers to openly discuss evidence-based best practices for pregnancy management using automated insulin delivery systems.The hosts also highlight the importance of clinician comfort with aggressive insulin automation during pregnancy, noting that increased basal modulation, suspensions, and automated adjustments should be expected as physiologic insulin needs fluctuate throughout gestation. Bellini stresses the importance of reducing patient burden while maintaining intensive glycemic management, tying this theme into Tandem's newly announced compatibility with the Dexcom G7 15-day sensor. Both hosts note strong patient enthusiasm for extending sensor wear time, framing reduced device maintenance as an important quality-of-life improvement even when the practical change appears modest.The discussion then shifts to immunotherapy in type 1 diabetes, focusing on the expanded approval of teplizumab to include children as young as 1 year old for delaying progression from stage 2 to stage 3 disease. Isaacs and Bellini underscore how broader eligibility may strengthen adoption of autoantibody screening among relatives of patients with type 1 diabetes. They review evidence showing that screening substantially lowers rates of diabetic ketoacidosis at diagnosis and discuss the broader clinical significance of delaying symptomatic disease onset, even when delays are shorter than the median duration reported in trials. The hosts note that many families value the possibility of a more gradual transition into insulin dependence, often requiring only minimal insulin therapy initially rather than presenting with severe metabolic decompensation.The conversation also addresses ongoing regulatory developments surrounding teplizumab for newly diagnosed stage 3 type 1 diabetes. Although the anticipated expedited review pathway has been withdrawn, the hosts remain optimistic about eventual approval, citing encouraging data and the growing role of precision medicine approaches in identifying patients most likely to benefit from immune intervention.To conclude the episode, Isaacs and Bellini examine a post hoc analysis from the SURMOUNT-5 trial comparing tirzepatide and semaglutide in adults with obesity and prediabetes. They discuss findings showing high rates of reversion to normoglycemia in both treatment groups, with tirzepatide demonstrating greater efficacy overall. The hosts frame these data within the broader movement to reconceptualize prediabetes as an earlier stage of type 2 diabetes and cardiovascular disease risk rather than a benign precursor state. They emphasize the potential value of earlier therapeutic intervention to prevent progression and reduce long-term cardiometabolic complications while also acknowledging the importance of maintaining multiple treatment options because of variability in medication tolerability and patient response.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Tandem Diabetes Care. Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes. April 27, 2026. Accessed May 8, 2026. https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-cares-control-iq-automated-insulin-delivery2: Sanofi. Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. April 22, 2026. Accessed May 8, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-32786503: Galindo RJ, Aronne LJ, Horn DB, et al. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. J Endocrinol Invest. Published online April 20, 2026. doi:10.1007/s40618-026-02895-3

 Tomorrow: Disneyland  Tonight: game plan.Type 1 diabetes doesn't mean missing out—it just means being prepared.Not chasing perfect numbers, just control + freedom. Adjust early, stay flexible, enjoy the moment.You don't have to choose between great blood sugars and a great life—you can have both. Keep up the fight. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Send us Fan MailRyan Schoonmaker has spent roughly two decades in medical device product development, building a career around solving hard engineering problems in high-stakes environments. Today he is the founder of Tight Line Solutions, where he works with growth-stage product development teams to reduce chaos, improve execution, and build the kind of systems that make technical organizations more efficient and predictable. His messaging consistently emphasizes that innovation is not just about ideas, but about disciplined execution, sound principles, and the ability to lead teams through complexity. Before launching Tight Line Solutions in late 2025, Ryan served as Director of Mechanical Engineering at Beta Bionics. Prior to that, he held senior R&D leadership positions at BD and spent more than seven years at Dexcom, progressing from Staff Mechanical Engineer to Director of Mechanical R&D. His background also includes product development work at Safety Syringes and Helbling Precision Engineering, where he worked on drug delivery systems, insulin-related devices, infusion sets, and other life science technologies. That combination of consulting, hands-on engineering, and executive leadership gives him a rare view across the full arc of product development.One of the most compelling parts of Ryan's story is that his work has touched products with enormous real-world impact. In his own words, helping bring the Dexcom G6 and G7 to market reinforced the lesson that meaningful innovation requires structure, rigor, and strong execution. Public patent records also show his name on multiple Dexcom-related design patents, reflecting direct involvement in device development. He pairs that technical depth with a strong focus on team culture, communication, and breaking large problems into manageable pieces—exactly the kind of perspective that resonates with engineers trying to grow into stronger technical leaders. Ryan also brings a strong academic foundation in mechanical engineering, with a B.S. from the University of Maryland and an M.S. from Tufts University, where his thesis focused on vibrotactile feedback in minimally invasive surgery. That blend of technical depth, medical device experience, and leadership philosophy should make for a rich conversation on product development, risk mitigation, engineering culture, and what it takes to build products that truly matter. LINKS:Guest LinkedIn: https://www.linkedin.com/in/ryan-schoonmaker-59048411/Guest website: https://www.linkedin.com/company/tight-line-solutions/Aaron Moncur, host  Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment like cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us at www.teampipeline.usWatch the show on YouTube: www.youtube.com/@TeamPipelineus 

Two-thirds of the Conspirituality staff have new books out: Matthew's AntiFascist Dad: Urgent Conversations with Young People in Chaotic Times and Derek's Well Enough:  Finding Health Despite the Wellness Industry. Julian "interviews" the co-hosts about themes of each book and their intersections with Conspirituality. But first, Derek discusses Glucose Goddess's recent partnership with medical device company, Dexcom. Show Notes The Sweet Embellishments of the Glucose Goddess Well Enough: Finding Health Despite the Wellness Industry Antifascist Dad by Matthew Remski Learn more about your ad choices. Visit megaphone.fm/adchoices

In 2024 Novo Nordisk announced it would discontinue Levimir insulin.. leaving many people scrambling and kind of stunned. There's no other insulin on the market quite like this long-acting – and it turns out the community wasn't letting it go without a fight. My guests are going to tell you more about why. I'm taking to Alison Smart, founder of The Alliance to Protect Insulin Choice – her daughter lives with type 1 as well as two doctors: Florence Brown and Amy Valent. Dr. Brown is Co-Director Joslin and BIDMC Diabetes in Pregnancy Program, Assistant Professor of Medicine, Harvard Medical School. Dr. Valent Assistant Professor of Obstetrics and Gynecology, School of Medicine at Oregon Health and Science University. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

When your blood sugar is doing the absolute most and you've already done everything “right”…

I've been talking to the folks at VIVI Cap for a few years now, it's been fun watching their progress. I wanted to catch up and find out more about what they've been up to when it comes to insulin storage  – especially as we get closer to the hot summer months. They launched new products in the last year – smart insulin storage that helps you track dosing and a new case with more cooling protection. My guest is Ron Nagar, the founder and CEO of TempraMed, the company that makes the VIVI Cap. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

“My blood sugar feels random…”Same food. Same insulin. Different day… different result.It's not random.

Ballinasloe's Beibhinn Parsons and Kilconly's Cliodhna Moloney-MacDonald have maintained their starting places in the Ireland team for Saturday's Six Nations clash against Italy, while Connacht's Anna McGann is also in the matchday squad. Following their opening day 33-12 defeat to England, Ireland are looking to bounce back against an Italian outfit who suffered a 40-7 reversal against France.  And even though Ireland won 54-12 when they met last year, the previous two tests went in favour of Le Azzure. Ireland captain Erin King was a try scorer in Round 1 and she looked ahead to the game with Galway Bay FM's William Davies, who asked her first how the Captain's Run went. == Kick-off at Dexcom Stadium on Saturday is 5.40pm and we'll have updates here on Galway Bay FM.

Former Ireland and Munster number 8 Anna Caplice joins Eoin Sheahan for this week's Wednesday Night Rugby, as Ireland prepare to host Italy in round 2 of the Six Nations in the Dexcom in Galway.Wednesday Night Rugby on Off The Ball with Bank of Ireland.

Insulin is slow… but you can make it work faster. If you're living with Type 1, remember this: you have more control than you think.From pre-bolus to simple “accelerators” like walking  or even a hot shower —small actions can make a big difference in your blood sugars.Stop just surviving. Start understanding. Start thriving. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Stacey mentioned these two groups:  Grownup T1Ds T1D to 100 Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

 CGM says “double arrows down” while driving… what would you do?  Most people panic… but there's a better way. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

From Clinical Need to Market: How Medical Devices Are Built w/ Stuart Broyles of MDM2 - AZ TRT S07 EP06 (288) 3-29-2026       What We Learned This Week:  Medical devices can take a decade to reach patients Bringing a medical device to market isn't quick. Phoenix is quietly becoming a major MedTech hub The Valley has a growing cluster of medical technology companies including: The biggest risk in medical innovation is building something doctors don't need One of the most common failures in MedTech is creating technology without validating the clinical problem first. Universities often invent the technology—but companies bring it to life Many medical device ideas originate in research labs. The future of healthcare innovation depends on collaboration Successful medical device innovation requires an ecosystem     Guest: Stuart Broyles, PhD LKIN: https://www.linkedin.com/in/stuart-broyles-phd/   Stuart builds connections that move ideas forward—from university research to real-world MedTech solutions. He was at WL Gore & Assoc. for nearly 3 decades working in MedTech at various levels and helped bring 13 devices to market. Also includes, university advisory roles, early-stage venture coaching, and innovation ecosystem development. Organization: MDM2 (Medical Device Manufacturing Multiplier)   Summary:  Medical devices can take a decade to reach patients Bringing a medical device to market isn't quick. While some devices can launch in six months to a year, many take five to ten years once clinical trials and regulatory approvals are involved. That's why early testing and feedback are critical. Phoenix is quietly becoming a major MedTech hub The Valley has a growing cluster of medical technology companies including: ·         Medtronic ·         Abbott Laboratories ·         Dexcom ·         West Pharmaceutical Services Add in research from Arizona State University and University of Arizona and the region is building a strong bioscience ecosystem. The biggest risk in medical innovation is building something doctors don't need One of the most common failures in MedTech is creating technology without validating the clinical problem first. Organizations like MDM2 (Medical Device Manufacturing Multiplier) are working to connect startups directly with clinicians early in the process so companies can refine their products before investing millions. Universities often invent the technology—but companies bring it to life Many medical device ideas originate in research labs. Universities typically own the patents and license the technology to startups or companies that can develop and commercialize the product. Programs like the ASU Skysong Innovation Center and Tech Launch Arizona help bridge the gap between research and business. The future of healthcare innovation depends on collaboration Successful medical device innovation requires an ecosystem: • clinicians who identify real problems • engineers who build solutions • investors who fund development • manufacturers who scale production Arizona is building that ecosystem through groups like MDM2 (Medical Device Manufacturing Multiplier) and the Phoenix Bioscience Core.       Podcast Show Notes Guest: Stuart Broyles, PhD LKIN: https://www.linkedin.com/in/stuart-broyles-phd/   Stuart builds connections that move ideas forward—from university research to real-world MedTech solutions. He was at WL Gore & Assoc. for nearly 3 decades working in MedTech at various levels and helped bring 13 devices to market. Also includes, university advisory roles, early-stage venture coaching, and innovation ecosystem development. Organization: MDM2 (Medical Device Manufacturing Multiplier) Episode Topic: How Medical Devices Move from Clinical Need to Market   Interview recorded: March 2026 Segment 1 – The Medical Device Industry What Are Medical Devices? Medical devices include a wide range of technologies used to diagnose, monitor, or treat patients. Common examples include: ·         Coronary stents used to treat blocked arteries in the heart ·         Artificial limbs and prosthetics ·         Implantable devices used in cardiology ·         Monitoring technologies such as glucose sensors A well-known example is the glucose monitoring technology produced by Dexcom, which operates in the Mesa, Arizona area. Medical devices also include technologies used to treat circulation issues in arms and legs, along with remote monitoring tools used in modern healthcare. History of the Industry Medical devices began emerging in the 1950s, but the real acceleration occurred between the late 1970s and the 1980s. This era introduced breakthroughs such as: ·         Coronary stents ·         Artificial hearts ·         Prosthetic limbs Over time, the technologies have become: ·         safer ·         more durable ·         more precise Phoenix as a MedTech Hub The Phoenix metro area has developed into a significant medical device and bioscience ecosystem. Major companies with a presence in the region include: ·         Medtronic ·         Abbott Laboratories ·         Dexcom ·         West Pharmaceutical Services This sector is particularly important in the Phoenix Valley, which has a rapidly aging population, increasing demand for medical technology and healthcare innovation. Importance of Clinical Partnerships Successful medical device development requires close collaboration with clinicians and hospitals. In the Phoenix ecosystem, companies often partner with: ·         HonorHealth ·         Mayo Clinic Universities also play a major role in research and collaboration, including: ·         Arizona State University ·         University of Arizona Clinicians provide feedback during development, helping companies ensure devices actually solve real-world clinical problems. How Long It Takes to Bring a Device to Market Development timelines vary widely: Typical timelines: ·         6 months – fastest case observed ·         1 year – simple device pathways ·         Up to 10 years – complex devices requiring clinical trials Segment 2 – Stuart Broyles' Career Stuart Broyles spent nearly 30 years at W. L. Gore & Associates (1995–2024). During that time he worked on multiple divisions developing cardiovascular and medical technologies. Key accomplishments include: ·         Participating in the commercialization of 13 medical devices ·         Working at the team member and leadership levels ·         Bringing complex devices through development and into the market Transition to Mentoring and Innovation After retiring in 2024, Broyles: ·         Did consulting and investing ·         Returned to the startup ecosystem ·         Became an Entrepreneur-in-Residence at Arizona State University He now works with startups through MDM2 (Medical Device Manufacturing Multiplier) helping early-stage companies navigate the development and commercialization process. Many of the companies he works with range from: ·         very early-stage startups ·         teams of just two or three founders ·         companies developing new medical manufacturing technologies MDM2 also partners with HonorHealth to help startups engage with clinical partners. Phoenix Innovation Infrastructure Several organizations contribute to the Valley's health technology ecosystem: Research and innovation hubs ·         Phoenix Bioscience Core ·         Flinn Foundation Startup programs ·         WearTech Center ·         ASU Skysong Innovation Center Medical device and engineering companies ·         PADT (3D printing and product development) ·         BD (Becton Dickinson) Wearable Technology Innovation The WearTech Center in central Phoenix supports startups building wearable medical technologies. Examples include companies such as: ·         Gravitrex ·         Hemasense One demonstration project includes a mock apartment designed to test monitoring systems for independent living seniors, helping companies validate technology in real-world environments. WearTech also hosts quarterly demo days where startups present their technologies to investors and industry partners. Segment 3 – Clinical Trials and Product Development The Need for a "Clinical Innovation Sandbox" A major challenge for startups is access to clinicians who can provide meaningful feedback during early development. MDM2 is working to create a system where: ·         startups can regularly meet clinicians ·         products can be demonstrated in person ·         real clinical feedback is gathered early This helps companies determine whether a product actually solves a meaningful healthcare problem. Continuing Medical Education (CME) Forums MDM2 is developing CME forums that allow clinicians to: ·         learn about emerging medical technologies ·         discuss product concepts ·         provide guidance during early development These sessions also create opportunities for honest feedback before expensive trials begin. One of the first sessions included collaboration with: ·         HonorHealth ·         Hemasense Clinical Trials Outside the United States Clinical trials in the U.S. can be complex and slow due to regulatory requirements. As a result: ·         many companies run trials in Europe or Asia ·         approval processes may be faster ·         testing costs may be lower Improving regulatory efficiency in the U.S. remains a challenge for medical device innovators. Intellectual Property and Universities Many medical technologies originate in universities. In these cases: ·         the university typically owns the intellectual property ·         companies license the technology to commercialize it Technology transfer organizations help bridge the gap between research and commercialization. Programs supporting this in Arizona include: ·         ASU Skysong Innovation Center ·         Tech Launch Arizona These programs help connect professors with entrepreneurs who have experience bringing products to market. Segment 4 – The Future of Medical Device Innovation in Phoenix Phoenix and Arizona are increasingly positioned as a national hub for bioscience and medical device innovation. Key advantages include: ·         strong manufacturing capabilities across the state ·         major university research centers ·         growing healthcare systems ·         startup accelerators and incubators New startups frequently spin out of larger companies like: ·         W. L. Gore & Associates ·         Medtronic These larger companies sometimes help fund and mentor new ventures. Building a Strong Innovation Ecosystem A successful innovation ecosystem requires collaboration among: ·         universities ·         hospitals ·         manufacturers ·         investors ·         startups Arizona is actively building this network to support long-term growth in the medical technology sector. Advice for Entrepreneurs For founders looking to build a medical device startup: 1.    Work with clinicians early in development 2.    Validate the problem you are solving 3.    Understand the regulatory pathway 4.    Build partnerships with universities and hospitals 5.    De-risk the concept before large investments Ultimately, success depends on proving value to three key stakeholders: ·         clinicians ·         investors ·         patients Organizations Mentioned Medical Device Manufacturing Multiplier MDM2 (Medical Device Manufacturing Multiplier)https://www.mdm2.org/ MDM2 works to strengthen Arizona's medical device manufacturing ecosystem through partnerships with universities, hospitals, and startups. WearTech Center WearTech Centerhttps://www.azweartech.org/projects Focus areas include: ·         wearable health technologies ·         remote monitoring systems ·         aging-in-place innovations   If you want to learn more about the growing medical device ecosystem in Arizona, visit the website for the MDM2 (Medical Device Manufacturing Multiplier) and explore how they're helping startups move innovations from the lab to the patient.     Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech   'Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/  

Waking up LOW every night?

Even when you do everything right… blood sugar can still spike.

 Living with Type 1 Diabetes isn't just physical — it's mental too. Imagine making hundreds of health decisions every single day… no breaks, no pauses, not even during sleep. From counting carbs to correcting blood sugar, it's a constant balancing act that most people never see.The exhaustion is real. The burnout is real. And the strength it takes? Also very real.Be kind. Be understanding. And if you're living with it — you're doing better than you think. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of topics that illustrate the rapidly changing landscape of our industry. We'll discuss everything from vaccine expansions to regulatory challenges, highlighting both the breakthroughs and hurdles faced by companies worldwide.Kicking off with GSK's recent achievement, their respiratory syncytial virus (RSV) vaccine, Arexvy, has gained FDA approval for adults aged 18 to 49 at increased risk of lower respiratory tract disease. This marks a significant milestone not only for GSK but also in the competitive RSV vaccine market where Pfizer and Moderna have already made their mark. This development underscores the industry's ongoing commitment to preventing RSV-related complications, reflecting the fierce competition driving innovation in vaccine development.In parallel, Gilead Sciences is making strides with its HIV pre-exposure prophylaxis medication, Yetztugo. The emphasis here is on how early production strategies can set a medication up for success by ensuring accessibility. This focus on manufacturing highlights a broader trend where efficient production methods are key to delivering timely healthcare solutions, underscoring the integral role manufacturing plays in modern drug development.Legend Biotech is navigating the competitive dynamics of the CAR-T therapy market with its treatment, Carvykti, despite facing competition from Johnson & Johnson's bispecific antibody Tecvayli. This scenario highlights strategic partnerships and market positioning challenges within oncology treatments, illuminating the complex landscape companies must navigate to succeed.On the regulatory front, Hyloris Pharmaceuticals encountered a setback when the FDA issued a Complete Response Letter due to manufacturing issues with its antiviral valacyclovir oral suspension. This incident serves as a reminder of the stringent manufacturing standards regulatory bodies demand and the essential nature of compliance in successful drug development.In an exciting advancement out of China, Neuracle Technology has developed the country's first brain-computer interface implant for paralyzed patients. This pioneering neurotechnology involves implanted EEG electrodes connected to a robotic glove capable of grasping objects. Such innovations highlight China's increasing role in cutting-edge medical technology development and represent a significant leap forward in rehabilitation for patients with severe disabilities.However, not all news is positive. Immutep faced an unexpected phase 3 failure with its LAG-3 candidate, which surprised analysts and led to a stock decline. These outcomes underscore the inherent risks in drug development and stress the importance of rigorous clinical evaluation to ensure both efficacy and safety.Shifting focus to diabetes management, companies like Insulet, Abbott, and Dexcom are expanding their efforts toward personalized care through continuous glucose monitors (CGMs) and insulin pumps. These advancements are part of an ongoing trend toward personalized diabetes management tools aimed at improving glucose control for patients.Meanwhile, Simtra Biopharma Solutions received an FDA warning due to contamination issues at one of its production facilities. This serves as a stark reminder of how crucial it is to maintain high-quality standards in drug manufacturing processes to avoid disruptions and ensure patient safety.Strategically speaking, we see notable shifts as companies like Eli Lilly invest in Asia and Pfizer enters obesity treatment markets through strategic partnerships. These moves highlight globalization trends as pharma companies seek to address high unmet medical needs in emerging markets.In a significant transition for BioNTech, founders Ugur Sahin and Ozlem Tureci are preparing to leave Support the show

Bonus episode! I had the opportunity to talk to the folks at Dexcom about their presentations at ATTD and I wanted to bring you the interview sooner rather than later. ATTD is the Advanced Technology and Treatments for Diabetes conference, this year it took place in Barcelona. If you're new around here, there are a few big diabetes conferences where studies are presented and news is made. ATTD in spring, ADA and ADCES in summer and a few more scattered here and there. We'll be sharing more from ATTD in upcoming interviews with other tech companies. But today I'm talking to Jessica Castle, VP of Medical Affairs at Dexcom – she's also an adult endocrinologist with a lot of clinical trial experience. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX     A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX   A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries.   Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy will lose patent protection in countries such as Brazil, China, and India later this month, and researchers identified 150 countries where it was never patented. These researchers estimated it will cost as little as $3 to produce a month's supply of semaglutide, which in its branded form sells for around $200 a month in the United States. Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate. https://www.sciencealert.com/weight-loss-drugs-could-cost-just-3-a-month-to-make-as-patents-end XX Here in the US the FDA is stepping up its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting telehealth companies it says make "false or misleading" claims about compounded versions of popular obesity drugs. The FDA says Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process." https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters XX   Check your infusion sets for an issue: Unomedical, a subsidiary of Convatec and a supplier of insulin infusion sets to diabetes tech firms, has received a warning letter from the FDA. Inspectors raised concerns with leaking infusion sets, following a regulatory assessment of Unomedical's facility in Reynosa, Mexico, last summer. Unomedical supplies infusion sets to insulin pump makers including Medtronic, Tandem Diabetes Care and Beta Bionics. In a Feb. 3 statement, Convatec said the letter focuses on reporting procedures and quality protocols and does not place restrictions on producing, marketing or distributing any of Unomedical's products.  Unomedical told the FDA in its responses that it plans to conduct a retrospective review of complaints involving serious injury or death by January and conduct additional training on complaint handling by May.   https://www.medtechdive.com/news/fda-warns-insulin-infusion-set-maker-unomedical-over-leaks-mishandled-comp/813503/ XX Nearly four in ten people with type 2 diabetes do not take their medications as prescribed, according to a new research review published in Diabetologia in November 2025.   Researchers examined existing studies on medication adherence, including how often patients miss doses, why it happens, and what strategies may help. They estimated that about 38% of patients with type 2 diabetes are not fully adherent to their medications.   Adherence rates vary depending on the type of medication. About 63% to 68% of patients take oral glucose-lowering drugs as directed, while adherence drops to 43% to 54% for injectable GLP-1 medications and 41% to 64% for insulin.   Poor adherence can lead to serious consequences. One retrospective study cited in the review found that patients who consistently took their glucose-lowering medications had a 31% lower risk of hospitalization or emergency department visits.   The review also highlighted ways to improve adherence. Simplifying medication routines can help, such as using fixed-dose combination pills, which combine multiple drugs into a single tablet. Studies show these combinations are linked to better adherence and improved blood sugar control.   Pharmacists can also play an important role by providing education, reviewing medications, setting up reminders, and helping patients organize their treatment plans. The researchers noted that support should be tailored to each patient. Older adults may benefit from simpler systems and caregiver support, while younger patients may respond better to digital tools like app-based reminders.   The authors also found that measuring adherence is challenging and recommend using multiple methods, such as pharmacy records, patient interviews, and objective tests when possible.   Overall, the review concludes that personalized, multi-step approaches lasting at least three months are most effective in helping people with type 2 diabetes stay on track with their medications. https://www.pharmacytimes.com/view/type-2-diabetes-medication-adherence-rates-remain-low-and-pharmacists-can-help XX New clinical trial shows metformin does not directly reverse insulin resistance in people with type 1 diabetes. Instead, it lowers the total amount of insulin required to keep blood glucose levels within the recommended range. The findings, published in Nature Communications, challenge long-held assumptions about how metformin works in type 1 diabetes. The results may help physicians refine treatment strategies and reduce the daily demands placed on people who rely solely on insulin therapy. "Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes," says Dr. Jennifer Snaith, endocrinologist and co-lead of the study.   https://scitechdaily.com/groundbreaking-trial-reveals-unexpected-benefit-of-metformin-in-type-1-diabetes/   Tech news ahead, including updates from Sensonics, Dexcom & Tandem.. right after this…. Back ot the wnews.. XX Sensonics shares that it's secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in the second half of 2026. Gemini builds on the implanted CGM to put the transmitter under the skin as well as the sensor. https://www.drugdeliverybusiness.com/senseonics-q4-2025-ide-gemini-cgm/ XX Medtronic Diabetes is now officially MiniMid, a stand alone public company. Medtronic  acquired MiniMed 25 years ago announed last May that it would spin its diabetes business off. In their statement the company points out that MiniMed is the only diabetes tech company to sell both insulin pumps and continuous glucose monitors.   https://www.investing.com/news/stock-market-news/medtronics-diabetes-unit-minimed-valued-at-53-billion-as-shares-fall-in-nasdaq-debut-4547518 XX Kevin Sayer heads back to Dexcom.. The former CEO is back in his position as executive chair of the Board, he'd stepped away for a medical leave. Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer's return to the board comes just days after Dexcom announced a new board member. Last week, the company announced that it added Google SVP, Platforms and Devices, Rick Osterloh, to its board as well.     https://www.drugdeliverybusiness.com/kevin-sayer-returns-dexcom-board-chair/ SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement.   Osterloh serves as Senior Vice President, Platforms & Devices at Google, where he oversees Android, Google Play, Chrome, and Google's hardware portfolio including Pixel phones, Google Nest devices, and Fitbit wearables. He has held this position since 2016.   https://www.investing.com/news/company-news/dexcom-appoints-google-executive-rick-osterloh-to-board-93CH-4529662 XX Sequel Med Tech announced broad national availability of its twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. After U.S. FDA clearance in 2024 and a controlled launch to optimize the twiist experience, the system is now fully available nationwide. The release says: Built on Sequel's proprietary iiSure™ Technology, the system enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems1, potentially reducing the risk of unexplained high glucose and giving you time to take action before experiencing severe high blood sugar or DKA2. Designed to expand access to automated insulin delivery, twiist is available through pharmacy channels with a flexible access model, XX Tandem Diabetes Care's Mobi automated insulin delivery system is now available with Android devices. In November, Tandem announced that it received FDA approval for the Android version of its Mobi mobile app. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year.   Tandem launched Mobi in the U.S. in February 2024. It initially received FDA clearance for people with diabetes ages six and up in July 2023. The system then received expanded clearance for pediatric indications in April 2024, then later won CE mark in May 2025.   Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the flagship Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve. https://www.drugdeliverybusiness.com/tandem-diabetes-care-launches-mobi-android/

 What if the cure for Type 1 Diabetes is closer than we think? Scientists are making huge breakthroughs with stem cells and insulin-producing beta cells that could change how this disease is treated forever. In this powerful discussion with Katie Beth Hand, we also hear the real story of what it's like living with Type 1 diabetes every single day.Hope, science, and the future of diabetes treatment—this is something worth watching. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Why don't we talk about our skin more?! When you or your child is diagnosed with diabetes, you quickly realize the skin is in for a rough time. Endless pokes from needles, infusion sets, CGM wires. You make it work, but what if there was a better way? I'm talking Marie Schiller and Kent Manson – they've teamed up to help with a solution now and one they're working on for the future. The available now treatment is Site Hero – a recovery patch to help sites heal.. and – for the future - a way to scan an area and help identify better injection or infusion sites at home. This is a great and practical conversation. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Site Hero and Healthy Sites here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

 Optimistic people don't ignore problems — they look for opportunity inside them.High blood sugar?Bad night of sleep?One of those diabetes days?You can spiral… or you can ask: “How can this work for me?”Your brain will find whatever you train it to look for. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In Episode 333, Coach Ken and Graham dive into a wide-ranging, honest conversation sparked by a viral question: Should Type 1 diabetes even be called diabetes?What started as a short social media clip turned into thousands of views, healthy debates, and emotional responses—highlighting the confusion, stigma, and misunderstanding that still surrounds diabetes today. Ken and Graham unpack why this topic struck such a nerve, how language shapes perception, and why clarity matters—not division.From there, the conversation expands into real-world diabetes challenges: insulin access and affordability, rationing fears, stress-driven insulin resistance, CGM infections, reusing supplies, and how everyday decisions—exercise, food quality, sleep, and stress—can dramatically change insulin needs.The episode closes with a thoughtful discussion on Dexcom's new 15-day CGM, environmental impact, patient assistance programs, and what progress actually looks like for people living with diabetes.This is raw, unscripted diabetes conversation—exactly what the live show is designed to be.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

If diabetes advice actually worked, you wouldn't be second guessing every meal, every dose, every CGM number.

In this episode of 'Back Seat Pundits' former Connacht and Ireland fullback, Gavin Duffy, joined Susanna Mollen as they travelled to the new Dexcom Stadium!On their way, they discuss Ireland's game against Italy, the online discourse around the outhalf position, and look forward to England in Twickenham. All with thanks to Renault Ireland | #RethinkRenault

Dan Deming sees the rotation trade continuing if markets can hold recent momentum this trading week. As for the Big 3, he sees a breakout candidate in Verizon (VZ), DexCom's (DXCM) potential to continue its recent upside momentum, and Applied Materials (AMAT) serving as a rising giant in the semiconductor trade. Dan offers example options trades for his Big 3 while Charles Schwab's Ben Watson takes investors through key levels for investors to watch. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

 As Type 1 diabetics, doing nothing isn't neutral — it's decline.There is no maintenance mode.Every single day we choose to intervene. We choose to fight.But this isn't just about insulin and numbers.It's burnout. Anxiety. Fear. Exhaustion.The mental weight no one sees.You can know what to do… and still struggle to do it if your mind isn't in the right place.We're diving deep into the Emotional Mechanics of Type 1 Diabetes.If you'd like to join the community and gain access to exclusive calls like this, you can learn more and sign up here: https://thewarriorstribe.com>> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Send a textMike Romance has spent nearly two decades operating at the intersection of manufacturing engineering, automation, validation, and operations leadership within the life-sciences ecosystem. His career spans startups and established organizations alike, with hands-on experience taking products from early development through GMP-ready, high-volume production. Across roles in process development, automation, quality systems, and manufacturing strategy, Mike has built a reputation for combining technical rigor with pragmatic execution.Most recently at Quantum-Si, Mike played a central role in scaling operations to support the commercialization of the Platinum protein sequencing platform while laying the groundwork for next-generation technologies like the Proteus platform. Working within a lean and highly agile leadership team, he helped establish scalable manufacturing foundations spanning CM-managed instrument supply, internal reagent kit production, and advanced silicon-based consumables—while navigating the realities of fast-moving product roadmaps and constrained resources.Earlier in his career, Mike held engineering and leadership roles at organizations including Illumina, Dexcom, GenMark Diagnostics, Truvian, and Encodia. Along the way, he's led pilot-line development, automation strategy, equipment qualification, validation programs, and process controls—often in environments where the path forward wasn't clearly defined.What sets Mike apart is not just his command of acronyms—GAMP, CQV, QbD, DFSS, FMEA—but his philosophy that systems only work when people do. He actively practices emotionally intelligent leadership, prioritizing trust, clarity, and psychological safety while still holding teams to high technical and operational standards. As Mike explores his next chapter, this conversation focuses on the lessons he's learned building resilient manufacturing systems—and the kind of organizations where he believes he can make the biggest impact next.LINKS:Guest LinkedIn: https://www.linkedin.com/in/mikeromance/Aaron Moncur, host The Wave is  a place for engineers to actively learn, share ideas, and engage with people doing similar work. Learn more at thewave.engineer Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us Watch the show on YouTube: www.youtube.com/@TeamPipelineus

We're often told blood sugar is all about what we eat, but that's only part of the story. Hormones, stress, sleep, and daily habits all play a major role in how our body manages glucose. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: UK looks at starting universal T1D screening, Dexcom's CEO mentions a new product, bariatric sugery vs GLP medications, FDA approves update to prescribing info for inhaled insulin, miscroplastic and diabetes link studied, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: (Stacey Track) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. We are less than one month from our first MNO of 2026. Please join us in Silver Spring MD Feb 20 and 21. It's going to be amazing. We're going to Nashville next March 6-7 and we're going to have a great event a Club 1921 we just added on Thursday March 5th for health care providers and patient leaders. All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX   All UK children could be offered screening for type 1 diabetes using a simple finger-prick blood test, say researchers who have been running a large study. This is the ELSA study - Early Surveillance for Autoimmune diabetes, a first of its kind UK study. They tested blood samples from 17,931 children aged 3-13 for autoantibodies, markers of type 1 diabetes that can appear years before symptoms. Families of children found to have early-stage type 1 diabetes received tailored education and ongoing support to prepare for the eventual onset of type 1 diabetes symptoms and to ensure insulin therapy can begin promptly when needed, reducing the chances of needing emergency treatment. Those with one autoantibody also received ongoing support and monitoring.   Some families were also offered teplizumab, the first ever immunotherapy for type 1 diabetes, which can delay the need for insulin by around three years in people with early-stage type 1 diabetes. The second phase has launched and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children (2-3 years) and older teenagers (14-17 years). The research team aims to recruit 30,000 additional children across these new age groups. ELSA 2 will assess how screening can be scaled across the NHS and evaluate its cost-effectiveness. https://www.birmingham.ac.uk/news/2026/childhood-type-1-diabetes-screening-is-effective-and-could-prevent-thousands-of-emergency-diagnoses XX At the J.P. Morgan Healthcare Conference Dexcom CEO Jake Leach says they're going to launch a new product outside the US. I'll link up that interview, The full quote: "When you look at the outside the U.S., there are a lot of structures that are tiered. Patients have access to different types of products, so we've got a new one that we want to introduce that will add flexibility there. It's based on the G7 platform, just like Dexcom ONE+, but it has a unique experience that's tailored for a subset of users that, today, don't have access to Dexcom." Your guess is as good as mine, but sounds more like a pricing or ordering issue than a new bit of hardware or software. Dexcom will also bring Stelo to some international markets this year. And plans a new mobile app experience for the wearable biosensor meant for people who don't dose insulin. Leach also says G8 will be much smaller and with more capability. but is a few years away. https://www.drugdeliverybusiness.com/dexcom-ceo-jake-leach-2026-roadmap-jpm/ XX A new international consensus statement provides guidance for the use of diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD).   Organized by the diaTribe Foundation, the document was based on evidence where available, as well as opinion from an international group of experts in endocrinology, diabetes technology, and obstetrics & gynecology, among others.   This is the first set of recommendations specifically addressing the use of diabetes technology in pregnancy – and we'll link it up. https://www.medscape.com/viewarticle/new-consensus-statement-addresses-diabetes-tech-pregnancy-2026a100020d XX Bariatric surgery beats GLP-1s for type 2 diabetes across income levels. This study was published this month, looking at nearly 300 patients are 4 medical centers. Success here is measured by lower blood glucose levels, higher weight loss (28% vs. 10%), less use of diabetes medications, remission of diabetes to the point of no longer needing to inject insulin, and reduced risk factors for cardiovascular disease.     Bariatric surgery was better than medical therapy across all social backgrounds, they found, and not just in areas of higher deprivation. The ancillary study was smaller, and some of the participants randomized in earlier stages crossed over from medical to surgical treatment, and the reverse. The authors acknowledged and accounted for these limitations, along with the rapid development of more powerful obesity drugs not fully captured in the study. This was a long term study – more than 12 years – and by the end of the study more people were choosing GLP1 medications. One dividing line: If someone hopes to lose 100 pounds, that's more likely with surgery than with medications.  "Ultimately, we need large, long-term, well-designed studies to clarify the best strategy for a given patient." https://www.statnews.com/2026/01/19/diabetes-study-bariatric-surgery-better-than-glp-1s/ XX Researchers at the University of California, Riverside have reported for the first time that a father's exposure to microplastics (MPs) can lead to metabolic problems in his children, including diabetes. This is a mouse study, but it looks at a previously unrecognized way in which environmental pollution may influence the health of future generations. MPs are extremely small plastic fragments, measuring less than 5 millimeters, that form as consumer products and industrial materials break down. Metabolic disorders describe a group of conditions that include elevated blood pressure, high blood sugar, and excess body fat, all of which raise the risk of heart disease and diabetes. The team found that female offspring of male mice exposed to MPs were far more prone to metabolic disorders than offspring of unexposed fathers, even though all offspring received the same high fat diet.     The research team hopes the findings will guide future investigation into how MPs and even smaller nanoplastics affect human development.   https://scitechdaily.com/microplastics-can-rewire-sperm-triggering-diabetes-in-the-next-generation/ XX The FDA has finalized four new recalls for certain lots of Abbott's FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to ongoing safety concerns. We told you about this in November when Abbott says some of its continuous glucose monitoring (CGM) sensors were providing incorrect low glucose warnings. Internal testing identified the issue—carbon building up in the sensors during the manufacturing process—and determined that approximately 3 million CGM sensors were affected. The sensors were distributed in the United States, Canada and several European countries.  When Abbott shared that announcement, the FDA was still reviewing the situation. No recalls had yet been finalized. Now, however, the agency has announced four new Class I recalls.   https://cardiovascularbusiness.com/topics/clinical/heart-health/fda-confirms-recalls-abbott-cgm-sensors-new-lawsuit-alleges-company-concealed-information XX   Insulet brings back it's U.S. Pod recycling program, now making it available to all U.S. customers. The Pod recycling program, offered at no cost to customers, enables users to request a recycling kit online. This allows them to return their used Omnipods. Insulet then decontaminates the returned Pods before transporting them to a company specializing in recycling for electronics and medical products. Insulet began recycling pilot programs in Mass and California and are rolling it out nationwide. Insulet also has "Pod takeback" programs outside the U.S. in several international markets. These programs enable customers to request a takeback kit by contacting their local customer support team.   https://www.drugdeliverybusiness.com/insulet-expands-us-pod-recycling-program/ XX Up next a new resource for a population at three times the risk for diabetes, but without a lot of access to health information. I The first diabetes information website primarily in ASL has launched. The site includes GIFs and videos on diabetes management and an ASL glossary of diabetes-related terms. This is from University of Utah Health – Called Deaf Diabetes Can Together. Deaf and hard of hearing people are at three times higher risk for diabetes, but access to health information in ASL is limited. https://healthcare.utah.edu/newsroom/news/2026/01/first-diabetes-information-website-asl-launches XX Novo Nordisk ended all work on cell therapies, including a Type 1 diabetes program, in October – and now has found a buyer. Aspect has acquired rights to the assets and giving Novo an option to reengage for later-stage development and commercialization. Novo is helping bankroll Aspect's development of the assets, investing in the company and providing research funding. The arrangement gives Novo a chance to profit from the programs down the line. Novo is eligible for royalties and milestone payments on future product sales and, having handed the reins to Aspect for now, can expand its role in later-stage development and commercialization. The integration will involve the transfer of capabilities and expertise from Novo sites in Denmark and the U.S. to Aspect's Canadian operations. https://www.fiercebiotech.com/biotech/novo-nordisk-offloads-diabetes-assets-aspect-amid-cell-therapy-retreat XX XX Lucas Escobar has carved a role by proving that healthcare marketing can be culturally resonant, commercially powerful and deeply human. As director and head of U.S. consumer marketing at Insulet, he has redefined how the Omnipod tubeless insulin pump shows up in culture, transforming a medical device into a symbol of identity, inclusion and empowerment.   Under Escobar's leadership, Insulet launched three breakthrough initiatives: Dyasonic: Sound of Strength, a Marvel comic collaboration introducing a superhero who uses Omnipod; The Pod Drop, which turned the sound of a pod change into a celebratory music track; and Omnipod Mango x Pantone, medtech's first color partnership, honoring the vibrancy of the diabetes community. Each blended creativity with purpose while driving results, helping fuel Omnipod's consistent double-digit growth and its position as the most prescribed insulin pump in the U.S.   Living with type 1 diabetes himself, Escobar brings lived experience to his work, using storytelling not just to sell, but to make people feel seen.   Click here to return to the 2026 MM+M 40 Under 40 homepage.   From the January 01, 2026 Issue of MM+M - Medical Marketing and Media https://www.mmm-online.com/40-under-40/40-under-40-lucas-escobar-insulet/ -- FDA approves an update to the prescribing info for Afrezza inhaled insulin. This is a revision to the recommendations for the starting mealtime dosage when patients switch from shots or insulin pumps. This is aimed at healthcare providers - the updated labeling was supported by results from the INHALE-3 trial. The FDA is still considering approval of Afrezza for kids – a decision there expect by summer. https://www.globenewswire.com/news-release/2026/01/26/3225442/29517/en/MannKind-Announces-FDA-Approval-of-Updated-Afrezza-Label-Providing-Starting-Dose-Guidance-when-Switching-from-Multiple-Daily-Injections-MDI-or-Insulin-Pump-Mealtime-Therapy.html   -- UK researchers have developed a calculator to predict whether someone is at risk for type 1 diabetes. They're hoping this helps in screening and in preventing DKA at diagnosis. They used the TEDDY study to create this calculator, which right now is in beta form and only for kids and teens ages 8-18. The current beta form of the calculator asks users to answer questions about four factors necessary to estimate a child's risk of developing type 1 diabetes: age, family history, number of confirmed autoantibodies, and genetic risk score. The calculator has been given regulatory approval as a diagnostic in the U.K., and he's working with a company that's hoping to bring it to the U.S. in the next few months in the form of a home genetic test kit. https://www.healthcentral.com/news/type-1-diabetes/new-calculator-might-help-predict-type-1-diabetes-before-symptoms-appear

When your child receives a new medical diagnosis, it can feel like the world shifts beneath your feet. Today's guest joins  Katie Taylor to share her daughter's Type 1 Diabetes journey—from dismissing "textbook" symptoms to navigating the financial challenges of families when it comes to chronic illness. This episode explores how one Mom moved from denial to "work mode" and how the HealthWell Foundation helps families afford life-saving medications. Sponsored in part by HealthWell Foundation—learn how you can help families afford life-saving medications at healthwellfoundation.org. Download our free Children's Hospital passport to empower your child to feel comfortable in the children's hospital. Resources Medical Support: Sanford Children's Hospital, Sioux Falls, SD. Nonprofit Support: HealthWell Foundation (Pediatric Assistance Grant). Community & Education: Children with Diabetes (10-year coins) and Stacey Simms (Diabetes Connections), Headstrong Foundation Connect with Alicia directly  Connect & Support Subscribe: Never miss an episode on Apple Podcasts or Spotify. Visit insidethechildrenshospital.com to easily search stories and episodes Follow us on Instagram for updates and opportunities to connect with other parents Download SupportSpot: receive Child Life tools at your fingertips.  Leave a Review: It helps other families find us and access our resources! Medical information provided is not a substitute for professional advice—please consult your care team. Keywords: Type 1 Diabetes, T1D diagnosis, HealthWell Foundation, pediatric healthcare, medical financial assistance, insulin costs, child life specialist, diabetes symptoms in kids, middle class healthcare help, medical debt, Dexcom, Omnipod, childhood chronic illness, parenting a diabetic child, Sanford Childrens Hospital, co-pay assistance, pediatric grants, medical parenting, T1D symptoms, diabetes advocate.

You walk the CES 2026 floor with Pete and Dave and quickly realize this episode is about practical gear that earns its place in your life. You hear about clever headphones, smarter thermostats, compact travel tech, and simple photo organization that fixes real annoyances without overthinking them. The crew cuts through the hype, calling out what feels thoughtful versus what just looks flashy, so you can spot the difference between tools that solve problems and gadgets that will gather dust. Then things get broader and more futuristic without losing focus. You explore consumer health tech that is finally becoming accessible, modular controllers that rethink how you interact with devices, and open-ear audio that fits real-world use. Robots take over yards and floors, smart calendars and water sensors aim to reduce daily friction, and networking gear shrinks without giving up power. It is a fast tour of ideas that are close enough to touch, if not already shipping, with one consistent reminder guiding the whole conversation: stay curious, stay selective, and Don't Get Caught chasing shiny things that do not actually improve your day. 00:00:00 Mac Geek Gab 1124 for Monday, January 12th, 2026 January 12th: National Curried Chicken Day MGG Monthly Giveaway – Enter to win a copy of Ecamm Live or Carbon Copy Cloner 7! The MGG Merch Store is Live! MGG's CES 2026 Sponsors: BusyCal (with code MACGEEK10)! Eero Ecamm for Zoom integration MacPaw CCC Backup Cool Stuff Found at CES 2026 00:03:41 TDM Twist Headphones 00:06:36 Eve Thermostat 00:08:08 FotoStax – $25 for a 10-pack 00:11:09 Targus Voyager EXP – $89.99 00:14:04 NOMATIC Travel Pack 00:15:52 Eloquens Email AI Autoresponder 00:21:25 Consumer-focused Blood Glucose Monitors Abbott Lingo, Stelo by Dexcom, Isaac from PreEvent, Y-Brush Halo, Actxa Core Smart Ring Sponsors 00:27:27 SPONSOR: Copilot Money. Your money, beautifully organized, now across every device. For a limited-time, get 26% off your first year when you sign up at https://try.copilot.money/macgeekgab. Get two months free with code ‘macgeekgab'. 00:28:49 SPONSOR: Shopify. In 2026, stop waiting and start selling with Shopify. Sign up for your one-dollar-per-month trial and start selling today at Shopify.com/MGG 00:30:25 SPONSOR: Gusto. Get three months free when you run your first payroll when you start at gusto.com/MGG MOAR Cool Stuff Found at CES 2026 00:31:33 Modue – Modular controllers for gamers, creators, and more 00:35:00 Shokz OpenFit Pro Earbuds 00:38:58 Robot Lawn Mowers Yarbo M-Series, Segway Navimow, Worx, Lymow 00:43:58 Robot Vacuums Eureka E10 Evo Plus – $299 Eureka Z50 $799 Roborock Saros Rover 00:51:13 Skylight Calendar 2 00:53:28 Droplet Smarthome Water Sensor from Hydrific 00:58:04 TP-Link Aireal Digital in-app assistant 01:00:31 TP-Link BE3600 Wi-Fi 7 Portable Travel Router TL-WR3602BE 01:03:21 CubicScreen.com 01:06:22 MGG 1124 Outtro MGG Monthly Giveaway Bandwidth Provided by CacheFly MGG's CES 2026 Sponsors Pilot Pete's Aviation Podcast: So There I Was (for Aviation Enthusiasts) The Debut Film Podcast – Adam's new podcast! Dave's Business Brain (for Entrepreneurs) and Gig Gab (for Working Musicians) Podcasts MGG Merch is Available! Mac Geek Gab YouTube Page Mac Geek Gab Live Calendar This Week's MGG Premium Contributors MGG Apple Podcasts Reviews feedback@macgeekgab.com 224-888-GEEK Active MGG Sponsors and Coupon Codes List BackBeat Media Podcast Network The Mac Geek Gab iPhone app Follow us on Mastodon Mac Geek Gab on Mastodon Adam Christianson on Mastodon Dave Hamilton on Mastodon Pilot Pete on Mastodon Mona for Mastodon (for Mac, iPhone, iPad) Adam Christianson on X/Twitter